Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
Vaxart, a clinical-stage biotechnology company, will host a conference call and business update on March 2, 2021, at 4:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vaxart, a clinical-stage biotechnology company, will host a conference call and business update on March 2, 2021, at 4:30 PM ET. The company specializes in developing oral recombinant vaccines that are tablet-administered rather than injected. Vaxart aims to create vaccines for various diseases, including coronavirus, Norovirus, and seasonal influenza, using a proprietary delivery platform that eliminates the need for refrigeration. This innovative approach also reduces the risk of needle-stick injuries.
Positive
- Development of oral vaccines for diverse diseases, potentially broadening market reach.
- Proprietary delivery platform enhances vaccine storage and shipment flexibility.
Negative
- Clinical-stage status may lead to uncertainties in product development timelines.
- Dependence on successful trials to commercialize vaccine candidates.
Details
News Market Reaction – VXRT
The recorded move for VXRT in the trading session of this news was +2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.
| Conference Call Dial-In & Webcast Information: | |
| Date: | Tuesday, March 2, 2021 |
| Time: | 4:30 PM Eastern Time |
| Domestic: | 877-407-0784 |
| International: | 201-689-8560 |
| Conference ID: | 13716984 |
| Webcast: | http://public.viavid.com/index.php?id=143739 |
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
| Contacts | |
| Brant Biehn Vaxart, Inc. 650 550 3500 IR@vaxart.com | Joyce Allaire LifeSci Advisors, LLC 617 435 6602 jallaire@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.